Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + Chemoradiation in HPV-Negative HNSCC
NCT05608369Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jun 2025
- Primary completion
- Aug 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in head and neck squamous cell carcinoma (HNSCC), sponsored by Case Comprehensive Cancer Center. Planned start Jun 2025; status: withdrawn.
02
Drugs
vorinostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05608369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608369.